Lucia Campetella, Antonio Farina, Macarena Villagrán-García, Marine Villard, Marie Benaiteau, Noémie Timestit, Alberto Vogrig, Géraldine Picard, Véronique Rogemond, Dimitri Psimaras, Marie Rafiq, Eve Chanson, Cecile Marchal, David Goncalves, Bastien Joubert, Jérôme Honnorat, Sergio Muñiz-Castrillo
BACKGROUND AND OBJECTIVES: Relapses occur in 15%-25% of patients with leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) autoimmune encephalitis and may cause additional disability. In this study, we clinically characterized the relapses and identified factors predicting their occurrence. METHODS: This is a retrospective chart review of patients with LGI1-Ab encephalitis diagnosed at our center between 2005 and 2022. Relapse was defined as worsening of previous or appearance of new symptoms after at least 3 months of clinical stabilization...
May 2024: Neurology® Neuroimmunology & Neuroinflammation